Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 958 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Day One Biopharmaceuticals Inc | DAWN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.37 | -2.26% | 16.01 | 09:11:27 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.38 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 14 | 958 | - | 9.67 - 18.0699 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:22:15 | 1 | $ 16.37 | USD |
Day One Biopharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.43B | 87.38M | - | 0 | -188.92M | -2.16 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Day One Biopharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DAWN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.00 | 18.00 | 16.1448 | 16.83 | 1,071,208 | -1.99 | -11.06% |
| 1 Month | 14.06 | 18.0699 | 13.02 | 15.73 | 1,833,048 | 1.95 | 13.87% |
| 3 Months | 15.22 | 18.0699 | 13.02 | 15.55 | 1,130,193 | 0.79 | 5.19% |
| 6 Months | 11.32 | 18.0699 | 10.90 | 14.91 | 799,754 | 4.69 | 41.43% |
| 1 Year | 13.62 | 18.0699 | 9.67 | 13.69 | 913,912 | 2.39 | 17.55% |
| 3 Years | 25.00 | 28.699 | 5.44 | 15.58 | 678,494 | -8.99 | -35.96% |
| 5 Years | 25.00 | 28.699 | 5.44 | 15.58 | 678,494 | -8.99 | -35.96% |
Day One Biopharmaceuticals Description
| Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. |
